4 results
The primary objective of this randomized, open label single centre trial is to compare dopamine versus no dopamine on top of standard treatment in patients with exacerbation of severe heart failure (NYHA class III-IV) in home situation. This study…
The primary efficacy objective of this study is to:* Compare the incidences of the composite endpoints of stroke, systemic embolic event (SEE), myocardial infarction (MI) and cardiovascular (CV) mortality between the edoxaban group and the…
The purpose of the study is to investigate how quickly and to what extent somapacitan is absorbed, metabolized (broken down) and eliminated from the body (this is called pharmacokinetics). Somapacitan will be labeled with tritium (3H, a radioactive…
* To assess the effect of Edoxaban versus vitamin K antagonist (VKA) on net adverse clinical events (NACE), i.e., the composite of all-cause death, myocardial infarction (MI), ischemic stroke, systemic thromboembolism (SEE), valve thrombosis, and…